Soru

Zorluk: ZorMonitoring and Treatment Evaluation

During morning rounds in the cardiac intensive care unit, the medical team reviews the chart of a 61-year-old female who was admitted five days ago for an acute anterior myocardial infarction complicated by a left ventricular mural thrombus. She has been receiving a continuous intravenous infusion of unfractionated heparin since admission. Her daily laboratory results show a platelet count of 88,000/mm388,000/\text{mm}^3, a precipitous decline from her baseline of 245,000/mm3245,000/\text{mm}^3 upon admission. On physical examination, she reports new-onset right lower extremity pain, and subsequent compression ultrasonography reveals an acute deep vein thrombosis in the right popliteal vein. Suspecting heparin-induced thrombocytopenia (HIT), the attending physician immediately discontinues the heparin infusion and initiates a continuous infusion of argatroban. The team discusses the long-term plan to discharge the patient on oral warfarin therapy.

Which of the following is the most appropriate protocol for monitoring this patient's recovery and transitioning her to the planned oral anticoagulant?

  1. Postpone the initiation of warfarin until the platelet count reaches at least 150,000/mm3150,000/\text{mm}^3, then overlap both medications for a minimum of 5 days.Cevap
  2. B
    Initiate warfarin concurrently with argatroban today and discontinue argatroban once the international normalized ratio is therapeutic for 48 hours.
  3. C
    Discontinue argatroban once the platelet count normalizes, and immediately begin warfarin monotherapy to minimize the risk of bleeding.
  4. D
    Transition the patient to a therapeutic dose of subcutaneous enoxaparin while awaiting platelet recovery, then initiate warfarin.
  5. E
    Order a serotonin release assay; if the result is negative, resume unfractionated heparin and initiate a standard warfarin bridge.

Cevap

Postpone the initiation of warfarin until the platelet count reaches at least 150,000/mm3150,000/\text{mm}^3, then overlap both medications for a minimum of 5 days.
The correct protocol for transitioning a patient with heparin-induced thrombocytopenia (HIT) to warfarin requires rigorous monitoring of the platelet count. Because warfarin rapidly depletes protein C (a natural anticoagulant) faster than it depletes prothrombin, it initially creates a transient hypercoagulable state. In a patient with active HIT, this can precipitate severe microvascular thrombosis, leading to warfarin-induced skin necrosis and venous limb gangrene. To prevent this, warfarin therapy must be postponed until the acute hypercoagulable state of HIT has resolved, which is indicated by a recovery of the platelet count to at least 150,000/mm3150,000/\text{mm}^3 (or the patient's baseline). Once this threshold is met, warfarin can be initiated, but it must be overlapped with a non-heparin anticoagulant (e.g., argatroban) for a minimum of 5 days AND until the international normalized ratio (INR) has been within the therapeutic range for at least 24 to 48 hours.

Adım Adım Çözüm

1
Analyze the clinical presentation.
The patient has a >50%>50\% drop in platelets and a new thrombosis on day 5 of heparin therapy, indicating a high probability of heparin-induced thrombocytopenia (HIT).
Recognizing the high pre-test probability (high 4T score) dictates immediate cessation of heparin and initiation of a non-heparin anticoagulant.
2
Evaluate the criteria for transitioning to warfarin.
Warfarin cannot be started during the acute phase of HIT. Platelets must recover to a safe threshold.
Warfarin causes a rapid decline in Protein C, a natural anticoagulant. In the setting of active HIT, this transient hypercoagulable state can lead to severe complications like venous limb gangrene.
3
Apply the standard bridging protocol for HIT recovery.
Wait until the platelet count is ≥150,000/mm3\ge 150,000/\text{mm}^3. Then, start warfarin and overlap it with the direct thrombin inhibitor (argatroban) for at least 5 days AND until the INR is therapeutic for 24-48 hours.
This specific sequence ensures the patient remains fully anticoagulated while protein C levels stabilize alongside the vitamin K-dependent procoagulant factors (II, VII, IX, X).

Anahtar Kavram

Monitoring and transitioning to oral anticoagulation in Heparin-Induced Thrombocytopenia (HIT)
Tahmini Süre:1m 30s
Bu soruyu puanla